Analysts lowered their price targets for Perspective Therapeutics after the company reported a smaller loss but lower sales.

Nov 10, 2026, 10:43 AM ETResultsRead the original at Benzinga

Neutral

Perspective Therapeutics' loss per share narrowed, but sales fell from $209,000 to $20,000 and both analysts lowered their price targets. Its reported trial progress is encouraging, but the results point in opposing directions.

CATX · Perspective Therapeutics Inc

AI read · Neutral

The AI's read

The smaller loss per share is encouraging, but sales fell and both analysts lowered their price targets. The CEO also described promising trial findings and progress in 2 other programs. Those reports are encouraging, but they do not show that the programs have changed sales. Together, the facts point in opposing directions.

Get alerts for CATX

Follow Perspective Therapeutics Inc (CATX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CATX

Free on the App Store and Google Play, or on the web.